AZN has been the topic of several other reports. Citigroup Inc. raised shares of Astrazeneca PLC to a buy rating in a research report on Wednesday, October 18th. Piper Jaffray Companies reissued a buy rating on shares of Astrazeneca PLC in a research report on Wednesday, August 9th. BidaskClub downgraded shares of Astrazeneca PLC from a hold rating to a sell rating in a research report on Monday, July 24th. Cowen and Company reissued a hold rating and issued a $34.00 target price on shares of Astrazeneca PLC in a research report on Friday, July 28th. Finally, Morgan Stanley downgraded shares of Astrazeneca PLC from an overweight rating to an equal weight rating in a research report on Friday, July 28th. Four analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. Astrazeneca PLC presently has a consensus rating of Hold and an average price target of $34.20.
Astrazeneca PLC (NYSE:AZN) opened at $33.46 on Wednesday. The firm has a market cap of $83,500.00, a P/E ratio of 7.94, a PEG ratio of 3.14 and a beta of 0.79. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 1.09. Astrazeneca PLC has a 1 year low of $25.55 and a 1 year high of $35.60.
Astrazeneca PLC (NYSE:AZN) last released its earnings results on Thursday, November 9th. The company reported $1.12 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.55. The business had revenue of $6.23 billion for the quarter, compared to the consensus estimate of $6 billion. Astrazeneca PLC had a net margin of 15.90% and a return on equity of 34.02%. The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period last year, the firm posted $1.32 earnings per share. research analysts predict that Astrazeneca PLC will post 1.93 EPS for the current year.
TRADEMARK VIOLATION WARNING: This piece was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://stocknewstimes.com/2017/11/19/astrazeneca-plc-azn-given-a-38-00-price-target-at-bmo-capital-markets-2.html.
Institutional investors have recently modified their holdings of the company. Intl Fcstone Inc. lifted its stake in shares of Astrazeneca PLC by 146.9% in the second quarter. Intl Fcstone Inc. now owns 32,549 shares of the company’s stock worth $1,110,000 after buying an additional 19,365 shares during the last quarter. Royal Bank of Canada lifted its stake in shares of Astrazeneca PLC by 12.2% in the second quarter. Royal Bank of Canada now owns 1,855,405 shares of the company’s stock worth $63,250,000 after buying an additional 201,885 shares during the last quarter. Assetmark Inc. lifted its stake in shares of Astrazeneca PLC by 9.0% in the second quarter. Assetmark Inc. now owns 208,714 shares of the company’s stock worth $7,115,000 after buying an additional 17,306 shares during the last quarter. Blair William & Co. IL lifted its stake in shares of Astrazeneca PLC by 62.3% in the second quarter. Blair William & Co. IL now owns 42,117 shares of the company’s stock worth $1,436,000 after buying an additional 16,174 shares during the last quarter. Finally, Buckingham Capital Management Inc. acquired a new stake in shares of Astrazeneca PLC in the second quarter worth $792,000. Institutional investors and hedge funds own 14.16% of the company’s stock.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.